Article
Medicine, General & Internal
Alexis L. Beatty, Noah D. Peyser, Xochitl E. Butcher, Jennifer M. Cocohoba, Feng Lin, Jeffrey E. Olgin, Mark J. Pletcher, Gregory M. Marcus
Summary: This study found that factors associated with greater odds of adverse effects after COVID-19 vaccination included receiving full vaccination dose, vaccine brand, younger age, female sex, and having a prior COVID-19 infection. Serious vaccine adverse effects were rare in this real-world cohort.
Article
Medicine, General & Internal
Ingmar Schaefer, Jan Hendrik Oltrogge, Yvonne Nestoriuc, Claire V. Warren, Stefanie Brassen, Maximilian Blattner, Dagmar Luehmann, Alexandra Tinnermann, Martin Scherer, Christian Buechel
Summary: Concerns about adverse effects can affect the uptake of COVID-19 vaccination. Research suggests that positive and negative expectations prior to vaccination are associated with systemic adverse effects. Understanding these associations can improve clinician-patient interactions and public vaccine campaigns.
Review
Immunology
Junfeng Zhang, Jiajia Cao, Qing Ye
Summary: New-onset and relapsed kidney diseases have been reported after COVID-19 vaccination, with minimal change disease, IgA nephropathy, antineutrophil cytoplasmic autoantibody vasculitis, and acute interstitial nephritis being the most frequent renal side effects. However, most patients responded well to treatment, indicating that the benefits of COVID-19 vaccination outweigh the risks. Healthcare professionals, especially nephrologists, need to be aware of these side effects and treat them promptly.
Article
Infectious Diseases
Ebrahim Babaee, Ali Amirkafi, Arash Tehrani-Banihashemi, Neda SoleimanvandiAzar, Babak Eshrati, Zahra Rampisheh, Mehran Asadi-Aliabadi, Marzieh Nojomi
Summary: This study investigated the adverse effects of the three most commonly used COVID-19 vaccines (Sinopharm, AstraZeneca, and Sputnik V) in Iran using a retrospective cohort study design. The results showed that Sputnik V had the highest rate of adverse effects, followed by AstraZeneca and Sinopharm. The COVID-19 vaccines used in Iran were found to be safe, with no reports of serious adverse effects.
BMC INFECTIOUS DISEASES
(2022)
Article
Immunology
Zhihua Li, Feng Hu, Qian Li, Shuang Wang, Chunli Chen, Yongpeng Zhang, Yu Mao, Xuehui Shi, Haiying Zhou, Xusheng Cao, Xiaoyan Peng
Summary: This study reports the clinical characteristics of ocular adverse events that occurred in China after vaccination with inactivated COVID-19 vaccines. The results indicate that there is no established relationship between inactivated COVID-19 vaccines and ocular disorders. Further investigation of the clinical spectrum is necessary.
Article
Medicine, General & Internal
Nicola P. Klein, Ned Lewis, Kristin Goddard, Bruce Fireman, Ousseny Zerbo, Kayla E. Hanson, James G. Donahue, Elyse O. Kharbanda, Allison Naleway, Jennifer Clark Nelson, Stan Xu, W. Katherine Yih, Jason M. Glanz, Joshua T. B. Williams, Simon J. Hambidge, Bruno J. Lewin, Tom T. Shimabukuro, Frank DeStefano, Eric S. Weintraub
Summary: This study conducted interim analysis of safety surveillance data of mRNA COVID-19 vaccines and found that the incidence of selected serious outcomes within 1-21 days post-vaccination was not significantly higher compared with 22-42 days post-vaccination. Surveillance is ongoing despite wide confidence intervals for many outcomes.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2021)
Letter
Medicine, General & Internal
Malini DeSilva, Jacob Haapala, Gabriela Vazquez-Benitez, Kimberly K. Vesco, Matthew F. Daley, Darios Getahun, Ousseny Zerbo, Allison Naleway, Jennifer C. Nelson, Joshua T. B. Williams, Simon J. Hambidge, Thomas G. Boyce, Candace C. Fuller, Heather S. Lipkind, Eric Weintraub, Michael M. McNeil, Elyse O. Kharbanda
Summary: This retrospective cohort study suggests that pregnant women who have been vaccinated against Covid-19 do not have a higher risk of clinically serious adverse events compared to those who are unvaccinated.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Rheumatology
Parikshit Sen, Naveen Ravichandran, Arvind Nune, James B. Lilleker, Vishwesh Agarwal, Sinan Kardes, Minchul Kim, Jessica Day, Marcin Milchert, Tamer Gheita, Babur Salim, Tsvetelina Velikova, Abraham Edgar Gracia-Ramos, Ioannis Parodis, Albert Selva O'Callaghan, Elena Nikiphorou, Tulika Chatterjee, Ai Lyn Tan, Lorenzo Cavagna, Miguel A. Saavedra, Samuel Katsuyuki Shinjo, Nelly Ziade, Johannes Knitza, Masataka Kuwana, Oliver Distler, Hector Chinoy, Vikas Agarwal, Rohit Aggarwal, Latika Gupta
Summary: This study assessed the safety of COVID-19 vaccines in patients with SAIDs compared to healthy controls. The results showed that SAID patients had a slightly higher risk of minor adverse events compared to the control group, but the absolute risk of major adverse events was small. There were minor differences in adverse events between vaccine types in SAID patients.
Article
Rheumatology
Georgina Nakafero, Matthew J. Grainge, Tim Card, Christian D. Mallen, Jonathan S. Nguyen Van-Tam, Hywel C. Williams, Abhishek Abhishek
Summary: This study investigated the association between COVID-19 vaccination and flare-ups of autoimmune rheumatic disease (AIRD). The results showed that COVID-19 vaccination was associated with a reduced risk of AIRD flares, regardless of prior COVID-19 infection, AIRD type, and mRNA or DNA vaccination technology.
Article
Dermatology
Reem Diab, Farnaz Araghi, Mehdi Gheisari, Zahra Asadi Kani, Hamideh Moravvej
Summary: We report two cases of lichen planus occurring after COVID-19 vaccination, possibly related to immune dysregulation and upregulation of T cell lymphocytes.
DERMATOLOGIC THERAPY
(2022)
Article
Immunology
Xiuju Chen, Xiaoxin Li, Haibo Li, Minghan Li, Songjian Gong
Summary: This case series reported potential ocular adverse events following inactivated COVID-19 vaccination. Some patients developed inflammation and other symptoms in their eyes, but the symptoms were relieved after steroid treatment and there was no recurrence.
Article
Medicine, General & Internal
Deshayne B. Fell, Tavleen Dhinsa, Gillian D. Alton, Eszter Torok, Sheryll Dimanlig-Cruz, Annette K. Regan, Ann E. Sprague, Sarah A. Buchan, Jeffrey C. Kwong, Sarah E. Wilson, Siri E. Haberg, Christopher A. Gravel, Kumanan Wilson, Darine El-Chaar, Mark C. Walker, Jon Barrett, Shannon E. MacDonald, Nannette Okun, Prakesh S. Shah, Shelley D. Dougan, Sandra Dunn, Lise Bisnaire
Summary: A population-based cohort study in Ontario, Canada found that COVID-19 vaccination during pregnancy was not significantly associated with an increased risk of adverse peripartum outcomes compared to vaccination after pregnancy or no vaccination.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2022)
Article
Immunology
Duy Cuong Nguyen, Thi Loi Dao, Thi Minh Dieu Truong, Thu Huong Nguyen, Thu Nga Phan, Ha My Nguyen, Thi Dung Pham, Xuan Bai Nguyen, Thanh Binh Nguyen, Van Thuan Hoang
Summary: This study investigated the adverse reactions and frequency of booster vaccination. The results showed that the adverse reactions were minor and had the same incidence rate as the first and second doses. More large-scale studies are needed to alleviate public concerns and increase vaccination rates.
Article
Multidisciplinary Sciences
Omeed Darweesh, Nasir Khatab, Ramiar Kheder, Thulfiqar Mohammed, Tola Faraj, Sabah Ali, Muath Ameen, Azad Kamal-Aldin, Mohammed Alswes, Naif Al-Jomah
Summary: Several mRNA and inactivated COVID-19 vaccines are available globally. This study provides evidence of adverse effects associated with COVID-19 vaccines among healthcare workers in Iraq and explores the attitudes of vaccine-hesitant healthcare workers. The study finds that most adverse effects are less prevalent in the second dose, and adverse effects related to the Pfizer vaccine are more prevalent in females. Participants who received two doses of the Pfizer vaccine have a significantly reduced prevalence of COVID-19 infection compared to those who received two doses of either the AstraZeneca or Sinopharm vaccines.
Article
Microbiology
Alireza Mohebbi, Majid Eterafi, Nasrin Fouladi, Majid Golizadeh, Reza Panahizadeh, Shahram Habibzadeh, Kimia Karimi, Elham Safarzadeh
Summary: This study investigated the early side effects of the BBIBP-CorV vaccine and found that systemic symptoms were the most commonly reported events after vaccination. Females and young people were more prone to experiencing side effects, while individuals with underlying chronic diseases reported fewer adverse reactions.
CURRENT MICROBIOLOGY
(2023)
Letter
Rheumatology
Gerasimos Evangelatos, George E. Fragoulis, Alexios Iliopoulos
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Letter
Rheumatology
Sindhu R. Johnson, Martin Aringer
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Letter
Rheumatology
Maria G. Tektonidou, Angela Tincani, Michael M. Ward
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Immunology
Nikolaos I. Vlachogiannis, Panagiotis A. Ntouros, Maria Pappa, Kleio-Maria Verrou, Aikaterini Arida, Vassilis L. Souliotis, Petros P. Sfikakis
Summary: This study found that the deregulated DNA damage response contributes to the proinflammatory environment in Behcet's disease. Reduced expression of NEIL1 is associated with increased DNA damage accumulation.
CLINICAL IMMUNOLOGY
(2023)
Article
Rheumatology
Gerasimos Evangelatos, George E. Fragoulis
Summary: JAK inhibitors have shown effectiveness in treating immune-mediated inflammatory diseases, but safety concerns regarding cardiovascular events and thromboembolic events have emerged. This article provides a critical analysis of major studies and suggests considering different risks in different IMIDs as well as assessing patients' cardiovascular and thromboembolic risk factors.
CLINICAL RHEUMATOLOGY
(2023)
Editorial Material
Rheumatology
Konstantina Magiouf, George E. Fragoulis
Article
Medicine, General & Internal
Konstantinos Thomas, Argyro Lazarini, Evripidis Kaltsonoudis, Paraskevi V. Voulgari, Alexandros A. Drosos, Argyro Repa, Ainour Molla Ismail Sali, Prodromos Sidiropoulos, Panagiota Tsatsani, Sousana Gazi, Kalliopi Fragkiadaki, Maria G. Tektonidou, Petros P. Sfikakis, Pelagia Katsimbri, Dimitrios Boumpas, Evangelia Argyriou, Kyriaki A. Boki, Konstantina Karagianni, Christina Katsiari, Gerasimos Evangelatos, Alexios Iliopoulos, Eleftheria P. Grika, Panagiotis G. Vlachoyiannopoulos, Theodoros Dimitroulas, Alexandros Garyfallos, Konstantinos Melissaropoulos, Panagiotis Georgiou, Constantinos Georganas, Periklis Vounotrypidis, Konstantinos Ntelis, Maria Areti, George D. Kitas, Dimitrios Vassilopoulos
Summary: The rate of pneumococcal vaccination among rheumatoid arthritis (RA) patients remains suboptimal, with 40% remaining unvaccinated. Severe disease, bDMARD use, comorbidities, and influenza vaccination were significant factors associated with pneumococcal vaccination, highlighting the need for cultivating a vaccination culture in RA patients.
FRONTIERS IN MEDICINE
(2023)
Article
Rheumatology
Konstantinos Thomas, Ioannis Grigoropoulos, Panagiota Alexopoulou, Emmanouil Karofylakis, Irene Galani, Kyriaki Korina Papadopoulou, Anastasia Tsiavou, Aliki Ntourou, Eleftheria Mavrou, Irina Qevani, Pelagia Katsimbri, Christos Koutsianas, Evgenia Mavrea, Dimitrios Vassilopoulos, Spyros Pournaras, Sotirios Tsiodras, Dimitrios Boumpas, Anastasia Antoniadou
Summary: This study examined the immune response to SARS-CoV-2 vaccination in rheumatic patients treated with rituximab. It was found that despite undetectable anti-spike antibodies in the serum, four out of ten patients showed lasting cell-mediated immune response. The cumulative dose of rituximab had an impact on both humoral and cell-mediated responses to the vaccine. Cell-mediated immune responses may serve as an important marker of vaccine efficacy against SARS-CoV-2.
Article
Rheumatology
Alexandros Panagiotopoulos, Konstantinos Thomas, Evangelia Argyriou, Aglaia Chalkia, Noemin Kapsala, Christos Koutsianas, Evgenia Mavrea, Dimitrios Petras, Dimitrios T. Boumpas, Dimitrios Vassilopoulos
Summary: This study aimed to evaluate the health-related quality of life (HRQoL) in patients with ANCA-associated vasculitides (AAVs) and compare it to rheumatoid arthritis (RA) and healthy controls (HC). The results showed that both AAV and RA patients had lower HRQoL compared to HC. HRQoL in AAV patients correlated with organ damage, while in RA patients, it correlated with disease activity and functional impairment/damage. Therefore, preventing organ damage and improving HRQoL are important goals for AAV therapies.
Article
Immunology
Aggelos Banos, Konstantinos Thomas, Panagiotis Garantziotis, Anastasia Filia, Nikolaos Malissovas, Antigone Pieta, Dimitrios Nikolakis, Alexandros G. Panagiotopoulos, Aglaia Chalkia, Dimitrios Petras, George Bertsias, Dimitrios T. Boumpas, Dimitrios Vassilopoulos
Summary: This study analyzed the transcriptome of ANCA-associated vasculitides (AAVs) and identified different molecular expression patterns and pathways, providing new potential targets for therapy.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Biology
Chrysoula G. Gialouri, Gerasimos Evangelatos, Alexios Iliopoulos, Maria G. Tektonidou, Petros P. Sfikakis, George E. Fragoulis, Elena Nikiphorou
Summary: With increasing life expectancy, psoriatic arthritis (PsA) in older individuals becomes more prevalent. We compared the clinical features, treatment approaches, and comorbidity profiles between late-onset and earlier-onset PsA patients. Late-onset PsA patients had lower odds of enthesitis but higher risks of dyslipidemia and major adverse cardiovascular events during the disease course.
Review
Rheumatology
Stamatia Katelani, George E. Fragoulis, Athanasios-Dimitrios Bakasis, Abraham Pouliakis, Elena Nikiphorou, Fabiola Atzeni, Theodoros Androutsakos
Summary: This study assessed the possibility of HBV reactivation in RA patients under anti-IL-6 treatment and found a higher risk in patients with CHB and a very low risk in patients with resolved HBV infection.
Article
Rheumatology
Nikolaos Kougkas, Konstantina Magiouf, Chrysoula G. Gialouri, Gerasimos Evangelatos, Maria Pappa, Aikaterini Dimouli, Alexios Iliopoulos, Anastasios Karmanakos, Theodoros Dimitroulas, Maria G. Tektonidou, Petros P. Sfikakis, George E. Fragoulis
Summary: This study examined the risk factors predicting uveitis development in spondyloarthritis (SpA) patients. It found that HLA-B27 and peripheral arthritis were risk factors for uveitis in axSpA patients, while family history of SpA, axial disease at diagnosis, and disease duration were risk factors for uveitis in PsA patients. The recurrence rate of uveitis was similar between axSpA and PsA patients. The study also found that ocular damage occurred more often in PsA patients than axSpA patients.
RHEUMATOLOGY INTERNATIONAL
(2023)
Article
Rheumatology
Alexandros Panagiotopoulos, Christos Koutsianas, Nikolaos Kougkas, Dimitra Moschou, Vasiliki-Kalliopi Bournia, Sousana Gazi, Maria G. Tektonidou, Dimitrios Vassilopoulos, Petros P. Sfikakis, George E. Fragoulis
Summary: This study reports the efficacy of switching to ixekizumab (IXE) after inadequate response to another interleukin-17 (IL-17) inhibitor (SEC) in psoriatic arthritis (PsA) patients. The results showed improvements in peripheral arthritis and skin involvement, as well as significant improvements in axial disease in patients with PsA. These findings suggest that IXE is effective in treating PsA patients, including those with axial disease, in a real-world setting.
RHEUMATOLOGY INTERNATIONAL
(2023)